Aberrant hypermethylation at sites -86 to 226 of DAB2 gene in non-small cell lung cancer

American Journal of the Medical Sciences

Volumn 349, Issue 5, 2015, Pages 425-431

  Li, Chang ^a,b   Chen, Jun ^a   Chen, Tengfei ^a   Xu, Zhenlei ^a   Xu, Chun ^a   Ding, Cheng ^a   Wang, Yuxuan ^a   Lei, Zhe ^a,b   Zhang, Hong Tao ^a,b   Zhao, Jun ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b Suzhou Key Laboratory for Molecular Cancer Genetics   (China)

Author keywords

Disabled 2; Methylation; Non small cell lung cancer

Indexed keywords

HUMAN DISABLED 2; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG; DAB2 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; AGED; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84928948183     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000436     Document Type: Article

References (31)

1. Li C, Xu C, Ma H, et al. Video-assisted thoracoscopic lobectomy with a single utility port is feasible in the treatment of elderly patients with peripheral lung cancer. Thorac Cancer 2014;5:219-24.
2. Liu Z, Zhao J, Chen XF, et al. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in nonsmall cell lung cancer. Lung Cancer 2008;62:15-22.
3. Zhong S, Fields CR, Su N, et al. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 2007;26:2621-34.
4. Liu RY, Zeng Y, Lei Z, et al. JAK/STAT3 signaling is required for TGF-beta-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol 2014;44:1643-51.
5. Sheng Z, He J, Tuppen JA, et al. Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2). Genomics 2000;70:381-6.
6. Mok SC, Chan WY, Wong KK, et al. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998; 16:2381-7.
7. Bagadi SA, Prasad CP, Srivastava A, et al. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Res Treat 2007;104:277-86.
8. Karam JA, Shariat SF, Huang HY, et al. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res 2007;13:4400-6.
9. Zhang Z, Chen Y, Xie X, et al. The expression of disabled-2 is common reduced in meningiomas. Neurol India 2014;62:57-61.
10. Tong JH, Ng DC, Chau SL, et al. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010;10:253.
11. Hannigan A, Smith P, Kalna G, et al. Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest 2010;120:2842-57.
12. Chao A, Lin CY, Lee YS, et al. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene 2012;31:764-75.
13. Yan ZX, Wu LL, Xue K, et al. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 2014;28:880-7.
14. Caslini C, Capo-chichi CD, Roland IH, et al. Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 2006;25:5446-61.
15. Du L, Zhao Z, Ma X, et al. miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene 2014;33: 4307-15.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001;25:402-8.
17. Zhang HT, Chen XF, Wang MH, et al. Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin Cancer Res 2004;10:2359-67.
18. Ren S, Kuang P, Zheng L, et al. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys 2012;64:155-60.
19. Chen C, Yin N, Yin B, et al. DNA methylation in thoracic neoplasms. Cancer Lett 2011;301:7-16.
20. Liu Z, Li W, Lei Z, et al. CpG island methylator phenotype involving chromosome 3p confers an increased risk of non-small cell lung cancer. J Thorac Oncol 2010;5:790-7.
21. Qian Q, Shi X, Lei Z, et al. Methylated +58CpG site decreases DCN mRNA expression and enhances TGF-beta/Smad signaling in NSCLC cells with high metastatic potential. Int J Oncol 2014;44: 874-82.
22. Mishra SK, Keyel PA, Hawryluk MJ, et al. Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adapter. EMBO J 2002;21:4915-26.
23. Hocevar BA, Mou F, Rennolds JL, et al. Regulation of the Wnt signaling pathway by disabled-2 (Dab2). EMBO J 2003;22:3084-94.
24. Penheiter SG, Singh RD, Repellin CE, et al. Type II transforming growth factor-beta receptor recycling is dependent upon the clathrin adapter protein Dab2. Mol Biol Cell 2010;21:4009-19.
25. Chaudhury A, Hussey GS, Ray PS, et al. TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol 2010;12:286-93.
26. Fazili Z, Sun W, Mittelstaedt S, et al. Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 1999;18:3104-13.
27. Mhawech-Fauceglia P, Kesterson J, Wang D, et al. Expression and clinical significance of the transforming growth factor-beta signalling pathway in endometrial cancer. Histopathology 2011;59:63-72.
28. Anupam K, Tusharkant C, Gupta SD, et al. Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol 2006;12:6041-5.
29. Xu HT, Yang LH, Li QC, et al. Disabled-2 and Axin are concurrently colocalized and underexpressed in lung cancers. Hum Pathol 2011;42: 1491-8.
30. Xie XM, Zhang ZY, Yang LH, et al. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers. Int J Oncol 2013;43:1636-42.
31. Huang Y, Friess H, Kleeff J, et al. Doc-2/hDab2 expression is upregulated in primary pancreatic cancer but reduced in metastasis. Lab Invest 2001;81:863-73.